Drug resistance: A growing problem

Drug Discovery Today

Volumn 15, Issue 15-16, 2010, Pages 583-586

  Peet, Norton P ^a  

^a MICROBIOTIX INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; BORTEZOMIB; DAPTOMYCIN; IMATINIB; OXAZOLIDINONE DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE; TRASTUZUMAB; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL MUTATION; CANCER RESISTANCE; COST CONTROL; DRUG INDUSTRY; DRUG RESEARCH; EDITORIAL; GENE MUTATION; HEALTH CARE ORGANIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS; PARASITOSIS; VIRUS INFECTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; COMMUNICABLE DISEASES; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS;

EID: 77955515262     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.04.002     Document Type: Editorial

References (21)

1. Tacconelli E., et al. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J. Antimicrob. Chemother. 2008, 61:26-38.
2. Muto C.A., et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect. Control Hosp. Epidemiol. 2003, 24:362-386.
3. Steenbergen J.N., et al. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J. Antimicrob. Chemother. 2005, 55:283-288.
4. Jarvis L.M. Antibiotics yo-yo. Chem. Eng. News 2010, 88:30-33.
5. Collier R. Drug development costs hard to swallow. Can. Med. Assoc. J. 2009, 180:279-280.
6. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
7. Oerlemans R., et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008, 112:2489-2499.
8. Lü S., et al. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp. Hematol. 2008, 36:1278-1284.
9. Kute T., et al. Development of herceptin resistance in breast cancer cells. Cytometry 2004, 57A:86-93.
10. http://www.fda.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/default.htm.
11. http://www.cdc.gov/drugresistance/healthcare/default.htm.
12. http://www.who.int/drugresistance/en/.
13. Schiffer C.A. Combating Drug Resistance-identifying Resilient Molecular Targets and Robust Drugs 2007, Royal Society of Chemistry, Computational and Structural Approaches to Drug Discovery, pp. 124-130 [chapter 7].
14. http://drug-resistance.org/.
15. http://www.dovepress.com/infection-and-drug-resistance-journal.
16. http://www.liebertpub.com/.
17. http://www.bentham.org/.
18. http://www.elsevier.com/.
19. Lefebre E., Schiffer C.A. Resilience to resistance of HIV-1 protease inhibitors: the success of darunavir. AIDS Rev. 2008, 9:131-142.
20. Nalam M.N.L., Schiffer C.A. New approaches to HIV protease inhibitor design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors. Curr. Opin. HIV AIDS 2008, 3:642-646.
21. Malik M., et al. Novel approach for comparing the abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob. Agents Chemother. 2010, 54:164-169.